Rifampin Injection — FDA Drug Shortage

Current — Mylan Institutional, a Viatris Company

The FDA lists a drug shortage record for Rifampin Injection (injection) from Mylan Institutional, a Viatris Company with status Current. The shortage was first posted on 02/17/2021. Reported reason: Demand increase for the drug

Shortage Details

Status
Current
Company
Mylan Institutional, a Viatris Company
Package NDC
67457-445-60
Dosage Form
Injection
Presentation
Rifampin, Injection, 600 mg/10 mL (NDC 67457-445-60)
Initial Posting
02/17/2021
Revised Date

Reason

Demand increase for the drug